Crescent Biopharma Inc. is a clinical-stage biotechnology company committed to developing innovative cancer therapies, with a particular focus on solid tumors. The company emerged from a strategic merger with GlycoMimetics, combining Crescent’s emerging oncology pipeline with GlycoMimetics’ platform and public market presence. This union was supported by a significant private investment from healthcare-focused institutions, positioning the company for long-term growth and robust clinical execution.
At the core of Crescent Biopharma’s pipeline is CR 001, a next-generation bispecific antibody that targets both PD 1 and VEGF. Designed to replicate and build upon the cooperative pharmacology of prior successful immunotherapies, CR 001 aims to offer improved efficacy in difficult-to-treat cancers such as non-small cell lung cancer. Alongside CR 001, the company is advancing two antibody-drug conjugates (CR 002 and CR 003), both featuring potent topoisomerase inhibitor payloads and being explored as monotherapies and in combination regimens.
Crescent Biopharma has built a leadership team with deep experience in oncology drug development, biologics manufacturing, and corporate strategy. This expertise supports its plans to progress its lead programs through early- and mid-stage clinical development, with a goal of demonstrating proof-of-concept for its unique therapeutic approach. The company’s structure and strategy reflect a commitment to high-impact translational science and disciplined execution.
With a clearly defined development roadmap and strong financial backing, Crescent Biopharma is positioning itself as a next-generation cancer therapeutics company. Its research emphasizes precision immunotherapy and innovative delivery platforms, aiming to reshape treatment paradigms for patients facing solid tumors that are often resistant to current standards of care.